PharmaPoint: Hepatitis C Virus – Italy Drug Forecast and Market Analysis to 2022

Publisher Name :
Date: 31-May-2013
No. of pages: 132

Summary

GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus – Italy Drug Forecast and Market Analysis to 2022”. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.

The main drivers of growth of the Italian HCV market are expected to be an increase in HCV awareness and the launch of next-generation HCV therapies.

The current market leader in Italy is Roche’s Pegasys (peginterferon alfa-2a). The current standard of HCV therapy in Italy is a combination of interferon and ribavirin. The less-frequent dosing of peginterferon compared with standard interferon (i.e., once a week compared with three times a week) enabled peginterferon to quickly capture market share. In addition to standard interferon, Pegasys directly competes for market share with Merck’s ViraferonPeg (peginterferon alfa-2b).

Scope

  • Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Italy from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Italy HCV market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HCV
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Italy

PharmaPoint: Hepatitis C Virus – Italy Drug Forecast and Market Analysis to 2022

Table Of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 11

3 Disease Overview 12
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Prognosis 17
3.2 Symptoms 17

4 Disease Management 18
4.1 Diagnosis and Referral Overview 18
4.2 Treatment Overview 19
4.3 Italy 22
4.3.1 Diagnosis 22
4.3.2 Clinical Practice 22

5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 23
5.3 Product Profiles – Major Brands 25
5.3.1 Incivek (telaprevir) 25
5.3.2 Victrelis (boceprevir) 30
5.3.3 Pegasys (peginterferon alfa-2a) 34
5.3.4 PegIntron (peginterferon alfa-2b) 39
5.3.5 Copegus, Rebetol, and Generic Ribavirin 43
5.3.6 Therapeutic Class: Interferon 46

6 Opportunity and Unmet Need 47
6.1 Overview 47
6.2 Unmet Needs 48
6.2.1 Unmet Need: Treatment Tolerability 48
6.2.2 Unmet Need: Efficacy 48
6.2.3 Unmet Need: Disease Awareness 49
6.2.4 Unmet Need: Treatment Cost 50
6.2.5 Unmet Need: Shorter Treatment Duration 50
6.2.6 Unmet Need: Simplified Treatment Regimens 51
6.3 Unmet Needs Gap Analysis 52
6.4 Opportunities 53
6.4.1 Opportunity: Pan-genotypic HCV Regimen 53
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 53
6.4.3 Opportunity: Involvement of Immune System 54

7 Pipeline Assessment 55
7.1 Overview 55
7.2 Promising Drugs in Clinical Development 56
7.2.1 Sofosbuvir and Sofosbuvir/Ledipasvir 58
7.2.2 Simeprevir 68
7.2.3 ABT-450 plus ABT-267 and ABT-333 76
7.2.4 Faldaprevir and Faldaprevir plus BI 207127 83
7.2.5 Daclatasvir and Daclatasvir plus Asunaprevir 91
7.2.6 Other Drug Classes 99

8 Market Outlook 102
8.1 Italy 102
8.1.1 Forecast 102
8.1.2 Key Events 106
8.1.3 Drivers and Barriers 106

9 Appendix 109
9.1 Bibliography 109
9.2 Abbreviations 117
9.3 Methodology 119
9.4 Forecasting Methodology 119
9.4.1 Percent Drug-Treated Patients 119
9.4.2 Patient Warehousing 120
9.4.3 Drugs Included in Each Therapeutic Class 120
9.4.4 Launch and Patent Expiry Dates 121
9.4.5 General Pricing Assumptions 121
9.4.6 Individual Drug Assumptions 122
9.4.7 Generic Erosion 124
9.4.8 Selection of Pipeline Agents 124
9.4.9 Pricing of Pipeline Agents 125
9.5 Physicians and Specialists Included in this Study 128
9.6 Survey of Prescribing Physicians 130
9.7 About the Authors 131
9.7.1 Author 131
9.7.2 Global Head of Healthcare 131
9.8 About GlobalData 132
9.9 Contact Us 132
9.10 Disclaimer 132

List Of Tables

Table 1: Modes of HCV Transmission 16
Table 2: Symptoms of Acute and Chronic HCV Infection 17
Table 3: HCV Genotypes Present in the 9MM 19
Table 4: General Standard of Care by HCV Genotype 19
Table 5: Treatment Guidelines for HCV by Country 21
Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013 21
Table 7: Leading Treatments for HCV, 2012 24
Table 8: Product Profile – Incivek 26
Table 9: Efficacy of Incivek in Treatment-Naïve Patients (ADVANCE Trial) 26
Table 10: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial) 27
Table 11: Common Incivek Adverse Drug Reactions 28
Table 12: Incivek SWOT Analysis, 2012 29
Table 13: Product Profile – Victrelis 30
Table 14: Victrelis Efficacy in Treatment-Naïve Patients (SPRINT-2 Trial) 31
Table 15: Victrelis Efficacy in Treatment-Experienced Patients (RESPOND-2 Trial) 32
Table 16: Victrelis SWOT Analysis, 2012 33
Table 17: Product Profile – Pegasys 35
Table 18: Antiviral Efficacy of Peginterferon alfa-2a Compared with Interferon alfa-2b 36
Table 19: Pegasys SWOT Analysis, 2012 38
Table 20: Product Profile – PegIntron 40
Table 21: Antiviral Efficacy of Peginterferon alfa-2b Compared with Interferon alfa-2b 40
Table 22: PegIntron SWOT Analysis, 2012 42
Table 23: Effect of Addition of Ribavirin to Peginterferon HCV Therapy 44
Table 24: Ribavirin SWOT Analysis, 2012 45
Table 25: Summary of Minor Therapeutic Classes, 2012 46
Table 26: Overall Unmet Needs – Current Level of Attainment 47
Table 27: Clinical Unmet Needs – Gap Analysis, 2012 52
Table 28: HCV – Pipeline, 2012 56
Table 29: Comparison of Therapeutic Classes in Development for HCV, 2012 57
Table 30: Gilead’s Sofosbuvir Ongoing Clinical Trials of Interest 59
Table 31: Product Profile – Sofosbuvir 60
Table 32: Sofosbuvir’s Most Common Adverse Effects 63
Table 33: Sofosbuvir SWOT Analysis, 2012 67
Table 34: Janssen’s Simeprevir Ongoing Clinical Trials of Interest 69
Table 35: Product Profile – Simeprevir 70
Table 36: PILLAR Clinical Trial Results 70
Table 37: Adverse Events Observed in PILLAR Clinical Trial 71
Table 38: Simeprevir SWOT Analysis, 2012 75
Table 39: AbbVie’s Combination Therapy Ongoing Clinical Trials of Interest 77
Table 40: Product Profile – AbbVie Combination Therapy 78
Table 41: AVIATOR Clinical Trial Results 78
Table 42: AbbVie Combination Therapy SWOT Analysis, 2012 82
Table 43: Boehringer Ingelheim’s Faldaprevir Ongoing Clinical Trials of Interest 84
Table 44: Product Profile – Faldaprevir 85
Table 45: Efficacy of Interferon-Free Faldaprevir Regimen (SOUND-C2 Trial) 85
Table 46: Faldaprevir SWOT Analysis, 2012 90
Table 47: Bristol-Myers Squibb’s Daclatasvir Ongoing Clinical Trials of Interest 92
Table 48: Product Profile – Daclatasvir 93
Table 49: Efficacy of Daclatasvir in Treatment-Naïve Patients (COMMAND-1 Trial) 93
Table 50: Daclatasvir and Asunaprevir Quad Therapy Efficacy 94
Table 51: Daclatasvir Triple Therapy Adverse Events 95
Table 52: Daclatasvir SWOT Analysis, 2012 98
Table 53: Comparison of Peginterferon lambda with Peginterferon alfa (EMERGE Trial) 99
Table 54: Efficacy of Alisporivir in Treatment-Naïve HCV GT2/3 Patients (VITAL-1 Trial) 100
Table 55: Sales Forecasts ($m) for HCV in Italy, 2012–2022 104
Table 56: Key Events Impacting Sales for HCV in Italy, 2012 106
Table 57: Italian HCV Market – Drivers and Barriers, 2012 106
Table 58: Key Launch Dates 121
Table 59: Key Patent Expiries 121
Table 60: Physicians Surveyed, By Country 130

List Of Figures

Figure 1: HCV Genome and Polyprotein Composition 13
Figure 2: HCV Lifecycle Overview 14
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012–2022 56
Figure 4: Sales for HCV Therapeutics in Italy by Drug Class, 2012–2022 105

  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Growth in the Indian Watch Industry
    Earlier, in India watches were seen as a luxury item. However, watches are now witnessing a fundamental change in perception, and are now gaining respect as an essential utility item. With the liberalization of the Indian market, coupled with the rising purchasing power of the young and consumerist Indians, watch industry in India seems to [...]
  • Global Retail Ready Packaging Market to Witness Steady Growth
    The market for retail ready packaging has witnessed impressive growth in recent years with boom in the retail industry. Retail ready packaging, also known as shelf-ready packaging is designed for the retail outlet, ready to be placed on shelf without any need for unpacking or repacking. In 2011, the global market for retail packaging was [...]
  • Global Hypertension Drugs Market 2014-2018
    Published: 4-Apr-2014        Price: US $2500 Onwards        Pages: 65
    Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. TechNavio's analysts forecas......
  • EpiCast Report: Allergic Rhinitis – Epidemiology Forecast to 2023
    Published: 1-Apr-2014        Price: US $3995 Onwards        Pages: 49
    Allergic rhinitis is a chronic respiratory disease characterized by inflammation of the nasal cavity and affects people of all ages. The main symptoms of allergic rhinitis are sneezing, nasal itching, blocked or runny nose and sore throat. Research suggests that a combination of genetic factors such as family history of allergic rhinitis and environmental factors such as exposure to allergens, including smoke, dust, pollen, insects, molds, or animal dander, may increase the risk for developing a......
  • Perennial Allergic Rhinitis – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 69
    Perennial Allergic Rhinitis - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Perennial Allergic Rhinitis - Pipeline Review, H1 2014', provides an overview of the Perennial Allergic Rhinitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Perennial Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and mole......
  • Tourette Syndrome – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 79
    Tourette Syndrome - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Tourette Syndrome - Pipeline Review, H1 2014', provides an overview of the Tourette Syndrome's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, an......
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 75
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2014', provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug t......
  • Dementia Associated With Alzheimer’s Disease – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 52
    Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2014', provides an overview of the Dementia Associated With Alzheimer's Disease's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Dementia Associated With Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug targe......
  • Chronic Back Pain – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 64
    Chronic Back Pain - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Chronic Back Pain - Pipeline Review, H1 2014', provides an overview of the Chronic Back Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, an......
  • Binge Eating Disorder – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 56
    Binge Eating Disorder - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Binge Eating Disorder - Pipeline Review, H1 2014', provides an overview of the Binge Eating Disorder's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Binge Eating Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with la......
  • Lewy body Dementia – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 39
    Lewy body Dementia - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Lewy body Dementia - Pipeline Review, H1 2014', provides an overview of the Lewy body Dementia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Lewy body Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs